Immune response and reactogenicity after immunization with two-doses of an experimental COVID-19 vaccine (CVnCOV) followed by a third-fourth shot with a standard mRNA vaccine (BNT162b2): RescueVacs multicenter cohort study

Ana Ascaso-Del-Rio,Javier García-Pérez,Mayte Pérez-Olmeda,Eunate Arana-Arri,Itziar Vergara,Carla Pérez-Ingidua,Mercedes Bermejo,María Castillo de la Osa,Natale Imaz-Ayo, Ioana Riaño Fernández,Oliver Astasio González,Francisco Díez-Fuertes, Susana Meijide,Julio Arrizabalaga, Lourdes Hernández Gutiérrez,Humberto Erick de la Torre-Tarazona,Alberto Mariano Lázaro,Emilio Vargas-Castrillón,José Alcamí,Antonio Portolés

eClinicalMedicine（2022）

引用 7|浏览16

暂无评分

摘要

Partly funded by the Institute of Health Carlos-III and COVID-19 Fund, co-financed by the European Regional Development Fund (FEDER) "A way to make Europe".

查看译文

关键词

COVID-19 vaccines,mRNA vaccines,Heterologous vaccination,BNT162b2,CVnCoV,Fourth dose,neutralizing antibodies,Boost doses of vaccines,Omicron,Experimental vaccines,Antibodies,Immune response

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要